Mesa Laboratories, Inc. (MLAB) Income Statement
MLAB FY2026 at a glance
Fiscal year ended March 31, 2026 · U.S. dollarsMLAB revenue and net income
Where MLAB's revenue goes
FY2026Each bar shows an amount and its share of revenue. MLAB kept 2.7% of revenue as net income.
MLAB profit margins
MLAB growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +3.4% | +4.4% | +13.2% | +11.4% |
| Gross profit | +4.9% | +5.8% | +12.7% | +11.9% |
| Operating income | +13.3% | +77.3% | +8.4% | +1.3% |
| Net income | — | +93.3% | +15.4% | −5.0% |
| EPS (diluted) | +5.9% | +13.9% | +9.8% | +9.5% |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
MLAB quarterly EPS vs estimates
Mesa Laboratories beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 5, 2026 (estimate $2.24).
MLAB income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $249.1M | $241.0M | $216.2M | $219.1M | $184.3M | $133.9M | $117.7M | $103.1M | $96.2M | $93.7M |
| Cost of revenue | $90.9M | $90.1M | $82.9M | $85.4M | $75.2M | $46.9M | $52.3M | $42.2M | $41.6M | $40.4M |
| Gross profit | $158.3M | $150.9M | $133.2M | $133.7M | $109.1M | $87.0M | $65.4M | $60.9M | $54.6M | $53.2M |
| Research & development | $20.3M | $19.5M | $19.3M | $20.5M | $15.8M | $10.4M | $6.4M | $3.5M | $3.5M | $4.2M |
| Sales, general & admin | $119.5M | $115.0M | $111.5M | $109.9M | $88.6M | $64.3M | $51.1M | $39.6M | $35.1M | $32.8M |
| Total operating expenses | $139.8M | $134.5M | $405.3M | $130.4M | $104.4M | $74.7M | $57.4M | $43.1M | $38.6M | $36.9M |
| Operating income | $18.5M | $16.3M | −$272.1M | $3.3M | $4.7M | $12.4M | $7.9M | $9.8M | $2.2M | $16.3M |
| Interest income | — | — | — | — | — | $107,000 | $960,000 | — | — | — |
| Interest expense | $10.7M | $11.9M | $5.7M | $4.8M | $3.9M | $8.0M | $5.5M | $0 | $1.9M | $0 |
| Income before taxes | $12.0M | $6.0M | −$275.6M | −$389,000 | $3.6M | $2.3M | $3.9M | $8.6M | $301,000 | $14.3M |
| Income taxes | $5.3M | $7.9M | −$21.4M | −$1.3M | $1.7M | −$971,000 | $2.1M | $1.1M | $3.3M | $3.1M |
| Net income | $6.7M | −$2.0M | −$254.2M | $930,000 | $1.9M | $3.3M | $1.8M | $7.5M | −$3.0M | $11.2M |
| EBITDA | $35.3M | $42.3M | −$238.4M | $37.5M | $32.5M | $28.0M | $22.4M | $35.4M | $9.8M | $25.1M |
| EPS (diluted) | $7.58 | $7.16 | $9.24 | $5.13 | $5.12 | $4.75 | $5.05 | $3.75 | $4.83 | $3.94 |
| Gross margin | 63.5% | 62.6% | 61.6% | 61.0% | 59.2% | 65.0% | 55.5% | 59.1% | 56.8% | 56.8% |
| Operating margin | 7.4% | 6.8% | −125.9% | 1.5% | 2.6% | 9.2% | 6.7% | 9.5% | 2.3% | 17.4% |
| Net margin | 2.7% | −0.8% | −117.6% | 0.4% | 1.0% | 2.4% | 1.5% | 7.3% | −3.1% | 11.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $60.1M | $63.7M | $65.1M | $60.7M | $59.5M | $62.1M | $62.8M | $57.8M | $58.2M | $58.9M | $53.5M | $53.2M |
| Cost of revenue | $21.1M | $17.1M | $23.3M | $23.4M | $27.0M | $23.7M | $23.1M | $22.4M | $20.9M | $22.3M | $20.1M | $21.1M |
| Gross profit | $39.0M | $46.6M | $41.8M | $37.3M | $32.5M | $38.4M | $39.8M | $35.5M | $37.2M | $36.6M | $33.4M | $32.1M |
| Research & development | $4.7M | $5.2M | $5.0M | $5.0M | $5.0M | $5.1M | $5.1M | $4.6M | $4.7M | $5.2M | $4.3M | $5.0M |
| Sales, general & admin | $27.3M | $34.2M | $28.8M | $27.6M | $18.0M | $31.8M | $28.9M | $27.3M | $26.9M | $28.1M | $29.2M | $27.2M |
| Total operating expenses | $32.0M | $43.9M | $33.8M | $32.6M | $29.4M | $36.9M | $34.0M | $31.9M | $31.7M | $307.8M | $33.5M | $32.2M |
| Operating income | $7.0M | $2.7M | $8.0M | $4.7M | $3.1M | $1.5M | $5.8M | $3.5M | $5.6M | −$271.3M | −$67,000 | −$60,000 |
| Interest expense | $2.4M | $2.6M | $3.0M | $2.9M | $2.2M | $2.5M | $2.8M | $3.0M | $2.8M | $1.9M | $1.9M | $905,000 |
| Income before taxes | $4.4M | −$1.6M | $4.6M | $2.0M | $7.0M | $461,000 | −$2.2M | $3.8M | $3.9M | −$275.3M | $1.9M | −$1.3M |
| Income taxes | $1.5M | $2.5M | $966,000 | −$477,000 | $2.3M | $7.6M | −$541,000 | $384,000 | $517,000 | −$20.7M | −$170,000 | −$95,000 |
| Net income | $2.8M | −$4.1M | $3.6M | $2.5M | $4.7M | −$7.1M | −$1.7M | $3.4M | $3.4M | −$254.6M | $2.1M | −$1.2M |
| EBITDA | $12.4M | $4.2M | $13.3M | $10.7M | $15.2M | $10.5M | $6.1M | $12.9M | $12.2M | −$267.1M | $12.9M | $7.7M |
| EPS (diluted) | $2.21 | $1.83 | $1.76 | $2.11 | $1.88 | $2.25 | $0.79 | $2.16 | $1.96 | $3.70 | $2.62 | $1.91 |
| Gross margin | 64.9% | 73.2% | 64.2% | 61.5% | 54.6% | 61.8% | 63.3% | 61.3% | 64.0% | 62.1% | 62.5% | 60.4% |
| Operating margin | 11.7% | 4.3% | 12.2% | 7.8% | 5.1% | 2.4% | 9.2% | 6.1% | 9.6% | −460.6% | −0.1% | −0.1% |
| Net margin | 4.7% | −6.5% | 5.6% | 4.1% | 8.0% | −11.4% | −2.7% | 5.9% | 5.8% | −432.2% | 4.0% | −2.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in MLAB's financial statements (latest annual report filed June 3, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
MLAB financial results
In fiscal year 2026 (ended March 31, 2026), Mesa Laboratories reported revenue of $249.1 million, up 3.4% from the year before. It had net income of $6.7 million, a net profit margin of 2.7%. Diluted earnings per share came to $7.58. Over five years revenue grew at an average rate of 13.2% a year.
See the MLAB stock overview for the latest quote and news, or the MLAB chart for price history and technical indicators.
MLAB income statement FAQ
What is Mesa Laboratories's annual revenue?
Mesa Laboratories reported total revenue of $249.1 million for fiscal year 2026, which ended on March 31, 2026. That was up 3.4% from $241.0 million the previous year.
Is Mesa Laboratories profitable?
Yes. Mesa Laboratories reported net income of $6.7 million in fiscal 2026, a net profit margin of 2.7%; its operating margin was 7.4%.
What is Mesa Laboratories's gross margin?
Mesa Laboratories's gross margin was 63.5% in fiscal 2026: for every $100 of revenue, Mesa Laboratories kept $64 after the direct cost of its products and services.
How much does Mesa Laboratories spend on research and development?
Mesa Laboratories spent $20.3 million on research and development in fiscal 2026, 8.2% of revenue.
How fast is Mesa Laboratories growing?
Revenue grew 13.2% a year on average over the last five fiscal years, from $133.9 million to $249.1 million.
What are Mesa Laboratories's earnings per share?
Mesa Laboratories earned $7.58 per diluted share in fiscal 2026, compared with $7.16 a year earlier.
When will Mesa Laboratories report its next earnings?
Mesa Laboratories is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes.
When does Mesa Laboratories's fiscal year end?
Mesa Laboratories's fiscal year ends in March. The latest annual report covers the year ended March 31, 2026 and was filed on June 3, 2026.